King et al., 2016 - Google Patents
Tumor-homing peptides as tools for targeted delivery of payloads to the placentaKing et al., 2016
View PDF- Document ID
- 6792334647844548155
- Author
- King A
- Ndifon C
- Lui S
- Widdows K
- Kotamraju V
- Agemy L
- Teesalu T
- Glazier J
- Cellesi F
- Tirelli N
- Aplin J
- Ruoslahti E
- Harris L
- Publication year
- Publication venue
- Science advances
External Links
Snippet
The availability of therapeutics to treat pregnancy complications is severely lacking mainly because of the risk of causing harm to the fetus. As enhancement of placental growth and function can alleviate maternal symptoms and improve fetal growth in animal models, we …
- 210000002826 Placenta 0 title abstract description 100
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| King et al. | Tumor-homing peptides as tools for targeted delivery of payloads to the placenta | |
| Wang et al. | FUNDC1-dependent mitochondria-associated endoplasmic reticulum membranes are involved in angiogenesis and neoangiogenesis | |
| Yang et al. | Conjugation of glucosylated polymer chains to checkpoint blockade antibodies augments their efficacy and specificity for glioblastoma | |
| Zhang et al. | Placenta-specific drug delivery by trophoblast-targeted nanoparticles in mice | |
| Waanders et al. | Kidney injury molecule‐1 in renal disease | |
| Paunescu et al. | Expression of the 56-kDa B2 subunit isoform of the vacuolar H+-ATPase in proton-secreting cells of the kidney and epididymis | |
| Lee et al. | MMP-9 gene deletion mitigates microvascular loss in a model of ischemic acute kidney injury | |
| Healey et al. | Antibody drug conjugates against the receptor for advanced glycation end products (RAGE), a novel therapeutic target in endometrial cancer | |
| Yang et al. | Fully Biocompatible Tantalum‐Based Antioxidant Nanoshields for Proximal Tubule Epithelial Cells‐Targeted Mitochondrial Holistic Protection in Acute Kidney Injury | |
| EP4497755A1 (en) | Anti-wnt-11 antibodies | |
| Xu et al. | Clinically Validated Leptin Receptor as a Target for Liposomal Delivery of Metformin in Endometriosis Therapy | |
| Kihara et al. | Nationwide epidemiological survey of acute pancreatitis in Japan | |
| Papachristou et al. | Alcohol abuse is a risk factor for pancreatic necrosis | |
| CN106139142A (en) | Application of the antibody specifically targeting WNT16B in the preparation of antitumor drugs | |
| Neri et al. | Hemoconcentration as an early marker of severity of acute pancreatitis | |
| Hackert et al. | Platelet inhibition reduces tissue damage in acute pancreatitis | |
| Lankisch et al. | Asymptomatic Hyperamylasemia and/or Hyperlipasemia: Their Incidence, Causes and Clinical Impact | |
| Ujiki et al. | Pancreatic cancer cell cycle arrest and apoptosis are induced by a novel depsipeptide sansalvamide analogue | |
| Neoptolemos et al. | Phase III Randomised Comparison of Gemcitabine (GEM) with Gemcitabine Plus Capecitabine (GEM-CAP) in Patients With Advanced Pancreatic Cancer | |
| Lee et al. | NADPH OXIDASE NOX4 MEDIATES PANCREATIC CANCER CELL SURVIVAL BY ACTIVATING JAK2 KINASE. INVOLVEMENT OF LMW-PTP PROTEIN TYROSINE PHOSPHATASE | |
| Aghdassi et al. | Depletion of Heat Shock Protein-70 (Hsp70) Causes Apoptosis in Pancreatic Cancer Cells | |
| Petcu et al. | CAUSES OF DECEASE IN NECROTIZING ACUTE PANCREATITIS | |
| Viterbo et al. | ANTI-REG I AND III ANTIBODY TREATMENT INDUCE CHANGES IN IMMUNOGLOBULIN LEVELS IN THE SODIUM TAUROCHOLATE MODEL OF ACUTE PANCREATITIS | |
| Rocha et al. | EFFECT OF RADIOLOGIC INTERVENTION ON MORTALITY IN NECROTIZING PANCREATITIS | |
| GENISTEIN | Meeting of the American Pancreatic Association, November 3–4, 2005 |